Rubiño, Francisco J.
Naranjo, Antonio http://orcid.org/0000-0002-2013-6664
Molina, Amparo
Fuentes, Sonia
Santana, Fabiola
Navarro, Ricardo
Montesdeoca, Arturo
Fernández, Tito
Lorenzo, José A.
Ojeda, Soledad
Funding for this research was provided by:
Universidad de las Palmas de Gran Canaria
Article History
Received: 7 March 2023
Accepted: 22 May 2023
First Online: 29 June 2023
Declarations
:
: The institutional review board of our hospital (CEIC Hospital Universitario de Gran Canaria Dr. Negrin; code NAR-OST-2011–02) approved the program protocol and the study. All participants provided written informed consent for their data to be used for research, including informed consent obtained from the next of kin or holders of healthcare power of attorney for dead patients. All procedures were carried out in accordance with the principles of the Declaration of Helsinki.
: AN has received research grants from Amgen-Fundación Canaria de Investigación Sanitaria, consulting fees from UCB, support for attending meetings and/or travel (Amgen, UCB, Pfizer, Abbvie) and speakers’ bureau fees from Amgen and Lilly. SO has received research grants from Amgen, support for attending meetings and/or travel (Amgen, UCB, Abbvie) and speakers’ bureau fees from Amgen and Lilly. AM has received speakers’ bureau fees from Amgen and Stada. The rest of the authors have no conflicts of interest to report. The authors declare that they have no conflict of interest for this work. Funding for open-access publication will be made through the Fundación Canaria de Investigación Sanitaria.